How can therapeutic drug monitoring be used to optimize inflammatory bowel disease treatment?

Biologic and biosimilar therapy, such as anti-TNF agents (e.g. infliximab, adalimumab, etc.), effectively treat moderate to severe inflammatory bowel disease (IBD). Therapeutic drug monitoring (TDM) serves as a cost-effective tool to ensure that patients receive appropriate and personalized treatment. Hear from Dr. Michael J Rosen, pediatric gastroenterologist from Stanford University, about the strengths and limitations of TDM for IBD.